CDSCO Panel nod to AstraZeneca Olaparib for BRCA Mutated HER2 Negative Breast Cancer
Advertisement
Based on the scientific data provided by the drug maker AstraZeneca, the Subject Expert Committee (SEC) functional under Central Drug Standard Control Organization (CDSCO) has given its nod for the additional indication of the anticancer Drug Olaparib film coated tablet 100/150 mg for breast cancer with adult patients with BRCA-mutated HaeR2- negative.
This came after the firm-presented interim report of the ongoing Phase IV clinical trial of Olaparib Film Coated Tablet 100/150 mg as per the condition of the permission (IMP-ND-189/2018) granted to the firm.
For more details, check out the fulls story on the link below:
AstraZeneca Olaparib Gets CDSCO Panel Okay For BRCA Mutated HER2 Negative Breast Cancer
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.